Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia.

Abstract

Experimental ischemia models have shown the antitussive dextromethorphan to be an N-methyl-D-aspartate antagonist with neuroprotective properties. We treated 10 patients with a history of recent stroke or transient ischemic attack with oral dextromethorphan (60 mg q.i.d.) for 3 weeks in a placebo-controlled, double-blind, crossover tolerance study. We documented no clinical evidence of toxicity attributable to dextromethorphan in this preliminary study.

• Authors: G W Albers, R E Sáenz, J A Moses Jr, D W Choi
• Journal: Stroke (Stroke) Vol. 22 Issue 8 Pg. 1075-7 (Aug 1991) ISSN: 0039-2499 [Print] United States
• PMID: 1866755 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Dextromethorphan

Topics

• Administration, Oral
• Aged
• Brain Ischemia (prevention & control)
• Cerebrovascular Disorders (drug therapy)
• Dextromethorphan (adverse effects, therapeutic use)
• Double-Blind Method
• Humans
• Ischemic Attack, Transient (drug therapy)
• Middle Aged
• Risk Factors